Black Diamond Gains as FDA Maps Accelerated-Approval Path for Silevertinib
FDA guidance on accelerated approval and a broad EGFR mutation definition may reduce uncertainty around Black Diamond’s silevertinib program.
J&J Seeks FDA Approval to Expand CAPLYTA Into Bipolar Mania
J&J’s CAPLYTA filing could create a fifth potential indication, broadening its psychiatric franchise even as JNJ shares were reported lower.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
ADC Therapeutics Pitches Zynlonta Expansion as a Commercial Growth Driver
ADC Therapeutics is emphasizing Zynlonta’s market opportunity and broader commercial availability as it seeks a more dur…
Merck Maps Out Its Post-Keytruda Growth Strategy With Nine New Medicines
Merck is positioning nine newer medicines and vaccines, including intismeran, as part of its strategy for the post-KEYTR…
Regeneron Buy Rating Reaffirmed After Fresh FDA Approval
Truist reiterated its Buy rating on $REGN after a new FDA approval, giving traders a concrete catalyst for reassessing i…
Q32 Bio Slides as Conference Commentary Raises Phase 3 Volatility
Q32 Bio shares fell 2.9% premarket after Phase 3 commentary at the Jefferies conference, underscoring the risks of small…
Biogen’s Mixed Alzheimer’s Data Leaves Investors Weighing CELIA’s Signal
Biogen’s two-year CELIA data showed broad clinical improvement at 60 mg, but the MMSE exception leaves investors weighin…
Bristol Myers Squibb’s KarXT Data Puts Schizophrenia Growth Story in Focus
Preliminary KarXT data puts Bristol Myers Squibb’s psychiatry pipeline under the microscope, with investors watching for…
GSK Wins FDA Approval for Nelkarmi After $10.6 Billion Nuvalent Acquisition
Nelkarmi’s FDA approval gives GSK an early validation point for its $10.6 billion Nuvalent acquisition and strengthens i…
Rythm Pharmaceuticals Jumps on Reported $150 Offer From Eli Lilly With CVR
Rythm Pharmaceuticals gained after a report of a $150-per-share Eli Lilly offer with a CVR, creating premium potential b…
Cardiff Oncology’s Phase III Push Puts Trial Durability in the Spotlight
Cardiff Oncology’s UBS conference update puts its Phase III timeline—and the durability question—at the center of the CR…